Could this pill help kids with dwarfism grow faster?
NCT ID NCT06164951
First seen Nov 12, 2025 · Last updated May 17, 2026 · Updated 27 times
Summary
This study tested a drug called infigratinib in 114 children aged 3 to 18 with achondroplasia, the most common form of dwarfism. The goal was to see if it could safely increase their growth rate over one year compared to a placebo. Participants had already been in an earlier observation study. The results may offer a new treatment option to improve height, but ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
QED Investigative Site
San Francisco, California, 94609, United States
-
QED Investigative Site
Aurora, Colorado, 80045, United States
-
QED Investigative Site
Baltimore, Maryland, 21287, United States
-
QED Investigative Site
Columbia, Missouri, 65212, United States
-
QED Investigative Site
Cincinnati, Ohio, 45229, United States
-
QED Investigative Site
Nashville, Tennessee, 37232, United States
-
QED Investigative Site
Madison, Wisconsin, 53792, United States
-
QED Investigative Site
Buenos Aires, Buenos Aires F.D., C1245AAM, Argentina
-
QED Investigative Site
Parkville, Victoria, 3052, Australia
-
QED Investigative Site
Edmonton, Alberta, T6G 2B7, Canada
-
QED Investigative Site
London, Ontario, N6A 5W9, Canada
-
QED Investigative Site
Ottawa, Ontario, K1H 8L1, Canada
-
QED Investigative Site
Montreal, Quebec, H3T 1C5, Canada
-
QED Investigative Site
Bron, 69677, France
-
QED Investigative Site
Paris, 75015, France
-
QED Investigative Site
Toulouse, 31059, France
-
QED Investigative Site
Rome, 00168, Italy
-
QED Investigative Site
Bergen, 5009, Norway
-
QED Investigative Site
Oslo, 0372, Norway
-
QED Investigative Site
Singapore, 229899, Singapore
-
QED Investigative Site
Málaga, 29010, Spain
-
QED Investigative Site
Vitoria-Gasteiz, 01008, Spain
-
QED Investigative Site
Bristol, BS2 8BJ, United Kingdom
-
QED Investigative Site
Glasgow, G51 4TF, United Kingdom
-
QED Investigative Site
London, SE1 7EH, United Kingdom
-
QED Investigative Site
Manchester, M13 9WL, United Kingdom
-
QED Investigative Site
Sheffield, S10 2TH, United Kingdom
Conditions
Explore the condition pages connected to this study.